Category: Daclatasvir
ITPC MENA IN THE REGIONAL CONSULTATION ON ACCELERATING ACCESS TO THE CONTIUUM OF HIV CARE: FOCUS ON HIV TESTING
Beirut, Lebanon, 12–14 July 2017 By the end of 2015, the estimated number of people living with HIV in the Region had reached 330 000. With a continuously growing epidemic coupled with low coverage of ART, standing at 14% of...
New WHO Guidance Report- Treatment Failure and Drug Resistance
WHO urges action against HIV drug resistance threat 20 JULY 2017 | GENEVA - WHO alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted in several countries. The Organization warns...
Amendment of the TRIPS Agreement
WTO members on 6 December 2005 approved changes to the WTO’s intellectual property (TRIPS) agreement in order to make permanent a decision on patents and public health originally adopted in 2003. This was formally built into the TRIPS Agreement after...
Launch of Moroccan Generic Sofosbuvir: A Victory for the Wide-spread Use HCV Treatment in Morocco
According to the Ministry of Health, 625,000 people are infected by HCV, 1.6% of the general population of Morocco. Of those infected, 267,000 people have active chronic infection requiring treatment. Until recently, the management of HCV infection has been hampered...
Treatment Advocates Denounce Gilead’s Embargo against Thousands of Tunisians Suffering from HCV Infection
The Tunisian Association of Fight against STDs and AIDS (ATL Tunis) and the International Treatment Preparedness Coalition in MENA Region (ITPC-MENA) denounce the refusal of Gilead Sciences to make their drug against the Hepatitis C Virus (HCV), sofosbuvir, available to...
The first Middle East and North Africa Community Advisory Board (MENA-CAB)
Casablanca, Morocco, 28 June-01 July 2014 Despite the fact that HIV prevalence in the countries of the Middle East and North Africa is believed to be low at least among the General Population, the rate of increase of new cases...